The standard busulfan-cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a preparative regimen in these patients
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial / Rambaldi, A., Grassi, A., Masciulli, A., Boschini, C., Micò, M.C., Busca, A., Bruno, B., Cavattoni, I., Santarone, S., Raimondi, R., Montanari, M., Milone, G., Chiusolo, P., Pastore, D., Guidi, S., Patriarca, F., Risitano, A.M., Saporiti, G., Pini, M., Terruzzi, E., et al.. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - 16:15(2015), pp. 1525-1536. [10.1016/S1470-2045(15)00200-4]
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial
RISITANO, ANTONIO MARIA;
2015
Abstract
The standard busulfan-cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a preparative regimen in these patients| File | Dimensione | Formato | |
|---|---|---|---|
|
#97 Rambaldi Lancet Onc 2015.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Accesso privato/ristretto
Dimensione
444.52 kB
Formato
Adobe PDF
|
444.52 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
